SIR, Professor Duthie misunderstands the purpose of our study, which was to examine the mechanism of the iron promoted synovial flare and not to evaluate the efficacy of this form of treatment of rheumatoid anaemia. As our article and Professor Duthie's letter point out many authors have described the synovial flare. We suggest that the reaction is mediated by iron (rather than dextran) promoted lipid peroxidation.
I have no criticism of Professor Duthie's haematological observations and failed to quote them only because our article did not address this issue. However, I would take the opportunity of describing the results of a study that was omitted from professor Duthie's extensive list of references. Bentley and Williams' gave iron dextran (800 mg intramuscularly) to 30 anaemic rheumatoid patients. Twenty six of the 30 patients showed a significant rise in haemoglobin at the two-month mark, but values fell back to the pretreatment level at nine months. The rise in haemoglobin was not related to pretreatment iron levels. They concluded and I quote: 'a therapeutic trial of parenteral iron will produce haematological improvement in the majority of anaemic patients and cannot therefore be taken as an indication that the anaemia was primarily due to iron deficiency. In the majority of anaemic rheumatoid patients, however, therapy should be directed at suppression of the activity of their rheumatoid disease, as this is the only current means by which lasting haematological improvement would be achieved'. Though we did not report the haematological indices in our patients, we occasions. Tests for ANA with serum diluted 1:16 on a substrate of rat liver slices were negative on every occasion for every patient included in the study. Two patients subsequently developed ANA at 20 and 25 months respectively after the anti-dsDNA were first noted. The other 18 patients remained consistently ANA negative and were tested on three to 12 occasions (mean 5-1).
During the first year after detection of anti-dsDNA there were no cases fulfilling the ARA preliminary classification criteria for SLE. During the second year one patient (of 13 who completed two years' follow up) fulfilled these criteria. At 25 months a second patient fulfilled the revised ARA criteria3 (which allows inclusion of antidsDNA as a feature) but had an 'inadequate' three features from the preliminary list. The remaining 18 cases failed to meet either list of ARA classification criteria on follow up of 14-60 months (mean 27 months) from the first detection of anti-dsDNA at high titre. Nine of these patients developed four or more features of SLE from a less restrictive list of disease features which we have previously used,4 but none of these would have been counted as SLE cases by Swaak and Smeenk.' The cause of the high anti-dsDNA titres in the remaining nine patients is unknown. None has any other connective tissue disease or liver disease (which may be associated with high titres).5
Thus when we used the same classification criteria as Swaak and Smeenk we observed a cumulative incidence of SLE of 0% at one year and 8% at two years from the detection of anti-dsDNA. These figures are much lower than found in their ANA positive group and should be borne in mind when viewing the prognostic implications of high anti-dsDNA titres in non-SLE patients who are ANA negative. 
